---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-24-000052"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T03:57:26.195477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M

## Summary
- Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.
- Advanced Diagnostics revenue declined 3% to $22M; consolidated net loss narrowed 12% to $27M.
- Adjusted EBITDA was $3M, a $10M improvement from -$7M in Q1 2023; cash and equivalents at $385M.
- FY 2024 guidance reaffirmed: revenue $650M-$660M (10-12% growth), Adjusted EBITDA $21M-$24M.
- CEO Chris Smith cited solid execution, NGS adoption growth, and consecutive revenue-per-test improvement.

## SEC filing metadata
- accession: 0001077183-24-000052
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/neo-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-24-000052
- JSON: https://secwatch.observer/filing/0001077183-24-000052.json
- Plain text: https://secwatch.observer/filing/0001077183-24-000052.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported the period ended March 31, 2024 results: revenue $156 million, net income Net loss of $27 million. Guidance reaffirmed.
  - Period: the period ended March 31, 2024
  - Revenue: $156 million
  - Net income: Net loss of $27 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.